THE BIO-KING REPORT: SLDB
Fintel reports that on June 24, 2024, Leerink Partners upgraded their outlook for Solid Biosciences (NasdaqGS:SLDB) from Market Perform to Outperform.
Analyst Price Forecast Suggests 160.53% Upside
As of June 12, 2024, the average one-year price target for Solid...